{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:58:00Z","timestamp":1789016280352,"version":"build-2803163510"},"reference-count":19,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,23]]},"DOI":"10.1182\/bloodadvances.2022007782","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T21:01:54Z","timestamp":1657054914000},"page":"4736-4739","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Loncastuximab tesirine in relapsed\/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-3377","authenticated-orcid":false,"given":"Juan P.","family":"Alderuccio","sequence":"first","affiliation":[{"name":"1Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun Z.","family":"Ai","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-2786","authenticated-orcid":false,"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"3The Christie National Health Service (NHS) Foundation Trust, Manchester Cancer Research Centre and Manchester Academic Health Science Centre, Manchester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[{"name":"4Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirit M.","family":"Ardeshna","sequence":"additional","affiliation":[{"name":"5Department of Haematology, University College of London Hospitals NHS Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Lunning","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hess","sequence":"additional","affiliation":[{"name":"7Hollings Medical Cancer Center, Medical University of South Carolina, Charleston, SC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier L.","family":"Zinzani","sequence":"additional","affiliation":[{"name":"8Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d and"},{"name":"9Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Universit\u00e0 di Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[{"name":"10Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[{"name":"11Humanitas University and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"12Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-6609","authenticated-orcid":false,"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"13Division of Oncology, Washington University, St Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ungar","sequence":"additional","affiliation":[{"name":"14Clinical Development, ADC Therapeutics America, Murray Hill, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turk","family":"Kilavuz","sequence":"additional","affiliation":[{"name":"14Clinical Development, ADC Therapeutics America, Murray Hill, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Yu","sequence":"additional","affiliation":[{"name":"14Clinical Development, ADC Therapeutics America, Murray Hill, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajuan","family":"Qin","sequence":"additional","affiliation":[{"name":"14Clinical Development, ADC Therapeutics America, Murray Hill, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-0464","authenticated-orcid":false,"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[{"name":"15Division of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"issue":"1","key":"2022081615223891300_B1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025","volume":"63","author":"Kanas","year":"2022","journal-title":"Leuk Lymphoma."},{"key":"2022081615223891300_B2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017","edition":"4th rev ed"},{"issue":"20","key":"2022081615223891300_B3","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"issue":"6","key":"2022081615223891300_B4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.hoc.2016.07.005","article-title":"The spectrum of double hit lymphomas","volume":"30","author":"Abramson","year":"2016","journal-title":"Hematol Oncol Clin North Am."},{"issue":"1","key":"2022081615223891300_B5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","article-title":"Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation","volume":"35","author":"Herrera","year":"2017","journal-title":"J Clin Oncol."},{"issue":"15","key":"2022081615223891300_B6","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood."},{"issue":"12","key":"2022081615223891300_B7","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol."},{"issue":"20","key":"2022081615223891300_B8","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022081615223891300_B9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol."},{"key":"2022081615223891300_B10","unstructured":"Magnusson\n              T\n            , NarkhedeM, MehtaA, GoyalG. No difference in overall survival between R-CHOP and R-EPOCH among patients with advanced stage MYC-rearranged, double hit, or triple hit diffuse large B-cell lymphoma [abstract]. EHA 2021 Virtual Congress; 9-17 June 2021. Abstract S224."},{"issue":"10","key":"2022081615223891300_B11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood."},{"issue":"19","key":"2022081615223891300_B12","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood."},{"issue":"6","key":"2022081615223891300_B13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"issue":"27","key":"2022081615223891300_B14","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol."},{"issue":"10254","key":"2022081615223891300_B15","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet."},{"issue":"10","key":"2022081615223891300_B16","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"2022081615223891300_B17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol."},{"issue":"7","key":"2022081615223891300_B18","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"2022081615223891300_B19","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"102","author":"Hamlin","year":"2003","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/16\/4736\/1913731\/advancesadv2022007782.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/16\/4736\/1913731\/advancesadv2022007782.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T15:22:59Z","timestamp":1660663379000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/16\/4736\/485791\/Loncastuximab-tesirine-in-relapsed-refractory-high"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":19,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,8,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007782","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]}}}